Massiver Turnaround bevorstehend?
Seite 1 von 33 Neuester Beitrag: 24.04.21 23:27 | ||||
Eröffnet am: | 27.08.15 18:08 | von: biotech1x1 | Anzahl Beiträge: | 812 |
Neuester Beitrag: | 24.04.21 23:27 | von: Manuelaheqv. | Leser gesamt: | 121.546 |
Forum: | Hot-Stocks | Leser heute: | 58 | |
Bewertet mit: | ||||
Seite: < | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... 33 > |
Mal schauen .
50 % des Kursziel von Seeking Alpha würden mir ja schon reichen, bin bescheiden :-)
Kann mir jmnd Infos drüber geben.
http://www.wsnewspublishers.com/...r-momo-inc-adr-nasdaqmomo/1526520/
Das mit der Shareanzahl lt. Yahoo (7,29 Mio.) kommt mir auch irgendwie merkwürdig vor.
Dann müßten die ja gestern gut 2 mal durchgehandelt worden sein wenn ich sehe, daß alleine an der NASDAQ rd. 13,7 Mio. Shares gehandelt worden sind (gut sicherlich einige doppelt und dreifach, aber trotzdem).
Da ist doch auch einiges an Warrents in letzter Zeit gelaufen ?
PS: Keine Handelsempfehlung! Falls jemand kursrelevante News/Fakten findet, bitte posten.
Great Basin Submits 510(k) Application to the FDA for Staph ID/R Blood Culture
14:20 31.08.15
SALT LAKE CITY --(BUSINESS WIRE)--
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that the Company has submitted its Staph ID/R Blood Culture Panel to the U.S. Food & Drug Administration (FDA) for 510(k) clearance. The submission of the Staph ID/R panel, the Company’s first multiplex panel, comes after the successful completion of a clinical trial that met all of Great Basin’s clinical objectives. Great Basin offers the first and only molecular diagnostic platform capable of low-plex tests, as well as multiplex and direct-from-specimen panels.
The Great Basin Staph ID/R Blood Culture Panel is a sample-to-result, automated, molecular multiplex panel that detects Staph aureus and two other staph species along with the mecA gene, a major drug resistance marker that confers resistance to methicillin and creates the superbug MRSA. In addition to Staph aureus, the panel also detects Staphylococcus lugdunensis and Staphylococcus epidermidis. The remaining staph species are detected as a group and identified as “Staphylococcus present.” When compared to traditional blood culture methods, results of this panel are expected to allow for a faster diagnosis and therefore a more timely appropriate therapy, which is associated with improved patient outcomes, lower treatment costs, and shorter length of hospital stay for affected patents.
“The successful trial completion and submission to the FDA of our Staph ID/R panel marks a significant milestone for Great Basin, and a critical advancement for our customers and hundreds of thousands of patients in the U.S. who are affected by staph bloodstream infections – including the deadly superbug MRSA – every year,” said Ryan Ashton, co-founder and Chief Executive Officer. “We are excited to submit our first multiplex panel to the FDA, and look forward to the value this test will add to the Great Basin platform, further setting us apart from other solutions in the molecular diagnostics space with superior scalability and cost efficiency.”
Ryan continued: “I am proud of the determination of the Great Basin team, which continues to execute at the highest level, delivering on the promise to provide current and future customers with a robust menu of easy-to-use and cost effective tests and panels. This panel will be higher value than our low-plex tests and increases our potential revenue per customer by offering higher revenue per test than either our C. diff test, or our GBS test.”
Once approved and commercially available, hospital and lab technicians can run the new multiplex panel on the same analyzer used to perform Great Basin’s commercially available low-plex tests for Clostridium difficile (C. diff) and Group B Streptococcus (GBS). Great Basin expects to offer the panel at a significantly lower cost than other blood panels on the market today, making fast, easy diagnosis of staph-caused blood sepsis affordable for the small to medium hospitals the Company targets. The Company’s unique scale to run a broad assay menu further enhances the economics for its customers, while also allowing Great Basin to grow their business with new and existing customers.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.
Forward-Looking Statements
This press release includes forward-looking statement regarding the Staph ID/R Blood Culture Panel and its effects upon the Company. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization, including the Staph ID/R Blood Culture Panel mentioned herein; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150831005609/en/
(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Einreichung FDA kann ja nicht sooooo schlecht sein wie der Kurs es meint uns vorzuspiegeln.
Wenn das Ding sooo geshortet wird, event. bekommen einige von denen heute kalte Füsse.
Ansonsten, irgendwann sollte ein Turnaround stattfinden und sei es nur technischer Natur.
Wer auch sein gesamtes Kapital verlieren möchte so wie ich, der investiere hier.
Mein nächster Nachkauf bei $0,2 danach gehts bewiesenermaßen immer nochmal 50 % abwärts!
Damit kann ich immerhin die nächsten Hochhäuser tapezieren, auch gut. Gewinn - Fehlanzeige
Finde darüber irgendwie nichts vernünftiges.
und
Pro forma for issuance of common shares subsequent to the end of the quarter, cash balance at Q1 quarter-end was approximately $22 million. Assuming our cash burn estimates are accurate, GBSN will exit 2015 with approximately $9M in cash (assuming no additional capital raises during the year), and will need to raise additional capital by sometime in 2016. Our modeled outstanding share count incorporates the assumption that future capital raises come in the form of common equity (or convertible debt, which is subsequently converted to equity).
Also beenden die wohl das Jahr 2015 mit 9 mil USD cash.